What Is the Prostate?
The prostate is a small gland — roughly the size of a walnut — located just below the bladder and in front of the rectum in men. It surrounds the urethra (the tube that carries urine and semen out of the body). The prostate's primary function is to produce seminal fluid, the liquid component of semen that nourishes and helps transport sperm.
Anatomical cross-section: prostate location relative to the bladder, urethra, seminal vesicles, and rectum. The prostate surrounds the urethra just below the bladder neck.
As men age, the prostate naturally grows larger — a non-cancerous condition called Benign Prostatic Hyperplasia (BPH) that affects more than half of men over age 60 and is one of the most common causes of elevated PSA.
Because the prostate surrounds the urethra, any condition that enlarges or inflames it can affect urinary flow. Not all prostate problems are cancer — in fact, most prostate-related symptoms in men over 50 are due to benign conditions.
What Is Prostate Cancer?
Prostate cancer occurs when cells in the prostate gland grow out of control. Like all cancers, it begins when the DNA inside a normal prostate cell undergoes mutations that cause it to divide uncontrollably.
Prostate cancer is the most common non-skin cancer in American men, with approximately 300,000 new cases diagnosed each year. However, the vast majority of prostate cancers are slow-growing and may not become life-threatening. This is why screening decisions require careful shared decision-making — not every detected cancer will require treatment.
🐢 Slow-Growing (Low Grade)
Many prostate cancers grow very slowly — taking years or even decades to become a clinical problem. These may be managed with active surveillance (careful monitoring without immediate treatment).
⚡ Aggressive (High Grade)
A minority of prostate cancers are aggressive and can spread to lymph nodes, bones, and other organs (metastasize) if not treated. Early detection through PSA screening can identify these before they spread.
How Does Prostate Cancer Develop?
Prostate cancer most often begins in the outer (peripheral) zone of the gland and typically starts as a microscopic focus of abnormal cells. Over time, without intervention, it can grow and potentially break through the prostate capsule, spread to nearby lymph nodes, and eventually metastasize to distant organs — most commonly bone.
Who Gets Prostate Cancer?
All men are at risk of developing prostate cancer with age. However, certain groups carry substantially higher risk:
Symptoms of Prostate Cancer
Early-stage prostate cancer typically causes no symptoms at all — this is exactly why PSA screening exists. When symptoms do occur, they often overlap significantly with symptoms of Benign Prostatic Hyperplasia (BPH), making it impossible to distinguish cancer from benign enlargement based on symptoms alone.
Urinary Symptoms
- Frequent urination, especially at night
- Difficulty starting urination
- Weak or interrupted urine stream
- Feeling that the bladder doesn't fully empty
- Pain or burning during urination
- Blood in the urine — always warrants evaluation
Sexual & Other Symptoms
- Blood in semen (hematospermia)
- Painful ejaculation
- Erectile dysfunction (can have many causes)
Symptoms of Advanced Disease
- Bone pain (especially in the lower back, hips, or pelvis)
- Unexplained weight loss and fatigue
- Leg weakness or swelling
Screening & Diagnosis
Prostate cancer screening involves testing men who have no symptoms. The primary screening tool is the PSA (Prostate-Specific Antigen) blood test — a simple blood test measuring PSA protein levels. An elevated PSA triggers further evaluation but does not confirm cancer.
The Digital Rectal Exam (DRE) is no longer recommended as a routine, first-line screening tool for prostate cancer.
The Diagnostic Pathway
Screening detects a signal. Diagnosis requires additional steps:
Elevated PSA → Confirm with repeat test (wait a few weeks to exclude transient causes)
PSA Density, %fPSA, PHI, 4Kscore — helps distinguish BPH from cancer
Imaging of the prostate — reported using PI-RADS scoring (1–5)
Tissue samples taken for laboratory analysis — the only way to definitively diagnose prostate cancer
How Is Prostate Cancer Graded?
If cancer is found on biopsy, it is graded to determine how aggressive it appears under the microscope. Two systems are used together:
Gleason Score
A pathologist examines the biopsy tissue and assigns a Gleason grade (1–5) to the two most common patterns of cancer cells seen. These two grades are added to produce the Gleason Score (ranging from 6 to 10).
Grade Groups (Modern System)
| Grade Group | Gleason Score | Risk Level | What It Means |
|---|---|---|---|
| Grade Group 1 | Gleason 6 (3+3) | Very Low / Low | Slowest-growing. Often suitable for active surveillance without immediate treatment. |
| Grade Group 2 | Gleason 7 (3+4) | Low-Intermediate | Predominantly slow-growing pattern. Treatment decisions individualized. |
| Grade Group 3 | Gleason 7 (4+3) | High-Intermediate | More aggressive pattern predominates. Treatment generally recommended. |
| Grade Group 4 | Gleason 8 (4+4) | High | Aggressive cancer. Treatment strongly recommended. |
| Grade Group 5 | Gleason 9–10 | Very High | Most aggressive. Highest risk of spread. Prompt treatment typically required. |
How Is Prostate Cancer Treated?
Treatment decisions depend on the cancer's Grade Group, PSA level, imaging findings, patient age, overall health, and personal preferences. Prostate cancer treatment is highly individualized.
For whom: Typically for Grade Group 1 (Gleason 6) and selected Grade Group 2 low-risk cancers.
What it involves: Regular PSA testing (every 3–6 months), repeat biopsies every 1–3 years, and periodic MRI. If the cancer shows signs of progression, treatment can then begin.
Goal: Avoid the side effects of treatment while catching any progression early. Research shows that many low-grade cancers never progress during a man's lifetime.
Active surveillance is not the same as "doing nothing." It is an active, guideline-endorsed management strategy with regular monitoring checkpoints.
What it involves: Surgical removal of the entire prostate gland and seminal vesicles, often with lymph node sampling. Increasingly performed as a robotic-assisted (da Vinci) minimally invasive procedure.
Benefits: Removes the cancer entirely; PSA should drop to near-zero after surgery; allows precise pathological staging.
Potential side effects: Urinary incontinence (affects approximately 15–20% of men at 1 year; most recover over time), erectile dysfunction (affects 40–65% depending on age and nerve-sparing technique). Most men regain urinary control within weeks to months.
Recovery: Typically 1–2 days in hospital; return to light activity in 2–4 weeks; full recovery 4–6 weeks.
There are two primary forms of radiation therapy for prostate cancer:
External Beam Radiation Therapy (EBRT): High-energy X-ray beams are directed at the prostate from outside the body. Modern IMRT (Intensity-Modulated Radiation Therapy) and SBRT (Stereotactic Body Radiation Therapy) allow very precise targeting with fewer treatment sessions.
Brachytherapy (Seed Implants): Radioactive seeds are placed directly into the prostate tissue, delivering radiation from inside. Can be combined with external beam radiation for higher-risk disease.
Potential side effects: Bowel changes (diarrhea, rectal irritation), urinary changes (frequency, urgency), and erectile dysfunction (30–50% at 2–3 years). Effects develop more gradually than with surgery and some may persist.
Prostate cancer cells use testosterone (androgen) to grow. Hormone therapy reduces testosterone levels in the body, slowing or stopping cancer growth.
Forms: Injections (leuprolide/Lupron, goserelin/Zoladex), oral medications (enzalutamide, apalutamide, abiraterone), or surgical removal of the testes (orchiectomy, rarely performed today).
Used for: High-risk localized cancer (combined with radiation), locally advanced cancer, metastatic disease, or when cancer returns after initial treatment.
Side effects: Hot flashes, fatigue, loss of libido, erectile dysfunction, mood changes, bone density loss, metabolic effects including increased risk of diabetes and cardiovascular disease. Regular monitoring and supportive care can help manage these.
For selected patients with localized, low-to-intermediate risk cancer in one region of the prostate, focal therapies aim to treat only the affected area while sparing the rest of the gland — potentially reducing side effects.
Examples: High-Intensity Focused Ultrasound (HIFU), cryotherapy, MRI-guided focused ultrasound (MRgFUS).
Current status: Still considered investigational at many centers. Evidence base is growing but long-term data are less mature than for surgery or radiation. Best discussed with an experienced urologist or radiation oncologist.
For metastatic or hormone-resistant (castration-resistant) prostate cancer, additional therapies may be used:
- Chemotherapy: Docetaxel and cabazitaxel are used in metastatic castration-resistant disease; docetaxel is also used upfront with ADT for high-volume metastatic disease.
- PARP Inhibitors: Olaparib, rucaparib, niraparib — effective in men with BRCA2, BRCA1, ATM, or other DNA repair mutations in the metastatic setting.
- Lutetium-177 PSMA Therapy (Lu-PSMA-617): A targeted radioligand therapy (Pluvicto) FDA-approved (2022) for PSMA-positive metastatic castration-resistant prostate cancer after prior taxane chemotherapy and novel hormonal therapy.
- Immunotherapy: Sipuleucel-T (Provenge) — a personalized dendritic cell-based immune therapy approved for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.